Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
GNHAY On Other Exchanges
SIX Swiss Ex
All times are local (Market data is delayed by at least 15 minutes).

galenica ag-unsp adr (GNHAY) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GALENICA AG-UNSP ADR (GNHAY)

Related News

No related news articles were found.

galenica ag-unsp adr (GNHAY) Related Businessweek News

No Related Businessweek News Found

galenica ag-unsp adr (GNHAY) Details

Galenica Ltd. engages in the development, manufacture, and distribution of pharmaceutical products in Switzerland and internationally. It operates through two business units, Vifor Pharma and Galenica Santé. The company offers iron replacement products, including Ferinject/Injectafer, Venofer, Maltofer, and Velphoro; immuno-stimulant products, such as Broncho-Vaxom and Uro-Vaxom; infectious diseases/OTX products, over-the-counter products, and herbal remedies; and synthetic and biotech drugs for use in immunology and the treatment of infectious diseases. It also markets products manufactured by third parties; provides products for patients suffering from chronic kidney disease; and develops and markets CellCept for various applications involving auto-immune diseases. In addition, the company offers pre-wholesale logistics services, including storage and distribution of products, and debt collection services to pharmaceutical and healthcare companies; supplies healthcare products to pharmacies, physicians, drug stores, care homes, and hospitals; and handles and coordinates product purchasing, sales, warehousing, and distribution of products for third parties. Further, it operates approximately 318 own pharmacies and 173 partner pharmacies under the Amavita and Sun Store brands in Switzerland; a chain of 61 own pharmacies in partnership under the Coop Vitality brand; MediService specialty pharmacy that offers medication for the treatment of patients in their own homes; and 161 Winconcept partner pharmacies. Additionally, the company provides master data systems for the healthcare market; publishes printed and electronic technical information on pharmaceutical products; maintains databases; offers management solutions under Triamun brand; TriaPharm total management software solution for pharmacies; TriaOne non-sector specific ERP solution for retail; and TriaMed software for physicians. Galenica Ltd. was founded in 1927 and is headquartered in Bern, Switzerland.

6,348 Employees
Last Reported Date: 03/11/15
Founded in 1927

galenica ag-unsp adr (GNHAY) Top Compensated Officers

Executive Chairman, Chairman of Governane & N...
Total Annual Compensation: SFr.3.8M
Compensation as of Fiscal Year 2014.

galenica ag-unsp adr (GNHAY) Key Developments

Galenica Ltd. - Analyst/Investor Day

Galenica Ltd. - Analyst/Investor Day

Galenica AG Proposes Two New Board Members

Galenica AG announced it has extended the contract of chairman Etienne Jornod until 2020 and will propose the appointment of two new board members in a bid to prepare the company for its planned split. On April 13, the company said it aims at ensuring the strategy's implementation by naming Marc de Garidel, CEO of French Ipsen, and Romeo Cerutti, member of the executive board of Credit Suisse Group Ltd., members of the company's board of directors.

Galenica Ltd. Announces Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Galenica Ltd. announced consolidated earnings results for the year ended December 31, 2014. For the year, EBIT was CHF 370.2 million compared to CHF 390.6 million a year ago. EBITDA was CHF 446.8 million compared to CHF 466.2 million a year ago. Net profit attributable to shareholders of the company was CHF 284.5 million compared to CHF 296.2 million a year ago. In 2014, the Galenica Group realised consolidated net sales of CHF 3,416.3 million. For the year 2015, management has set itself the target of achieving at least the same level of profit in 2015 as in the previous year, both before and after deduction of minority interests.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNHAY:US $0.00 USD 0.00

GNHAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardinal Health Inc $84.35 USD +0.67
Celesio AG €26.19 EUR -0.063
McKesson Corp $226.85 USD +0.11
UDG Healthcare PLC 491.10 GBp +4.00
Walgreens Boots Alliance Inc $96.58 USD +0.36
View Industry Companies

Industry Analysis


Industry Average

Valuation GNHAY Industry Range
Price/Earnings 25.2x
Price/Sales 2.0x
Price/Book 4.2x
Price/Cash Flow 19.9x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALENICA AG-UNSP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at